This considered, the present review is focused on the cellular events or molecular pathways which make HIV-protease inhibitors, HIV-reverse transcriptase inhibitors or CXCR4 antagonists capable of impairing the formation of new vessels that accompanies and favors tumor progression. Here, CXCR4 is linked to neoplasm.